T-E PHARMA, founded by "Father of Antibodies" Dr. Chang Tse-wen, is preparing for a 2026 listing on the Emerging Stock Market. The group, encompassing Immunowork and D-I Biotech, currently has five candidates at critical clinical junctures.

• Core Platforms: The group’s proprietary platforms include Fatty Acid Modification, Multi-arm Linkers, and Antibody-Drug Conjugates (ADC), covering metabolic, neuroendocrine, and oncological indications.
• Key Pipeline Assets:
• TE-8105 (GLP-1): An ultra-long-acting GLP-1 analog for metabolic diseases. Phase 2B trials were initiated in Q4 2025; 2026 will be a critical year for clinical data readout and licensing valuation.
• TE-8214: A modified octreotide analog targeting neuroendocrine tumors and acromegaly, currently in Phase 2 trials.
• Capital Strategy: The company plans to use the parent entity as a capital platform to integrate group R&D results, pursuing international licensing and strategic partnerships to unlock the value of its technology platforms.

Resource: 5新藥臨床邁大步 T-E PHARMA拚登興櫃